Epithelial ovarian cancer (EOC) spreads by direct dissemination of malignant cells and multicellular clusters, known as spheroids, into the peritoneum followed by implantation and growth on abdominal surfaces. Using a spheroid model system of EOC metastasis, we discovered that Liver kinase B1 (LKB1), encoded by the STK11 gene, and its canonical substrate AMP-activated protein kinase (AMPK) are activated in EOC spheroids, yet only LKB1 is required for cell survival. We have now generated STK11-knockout cell lines using normal human FT190 cells and three EOC cell lines, OVCAR8, HeyA8, and iOvCa147. STK11KO did not affect growth and viability in adherent culture, but it decreased anchorage-independent growth of EOC cells. EOC spheroids lacking LKB1 had markedly impaired growth and viability, whereas there was no difference in normal FT190 spheroids. To test whether LKB1 loss affects EOC metastasis, we performed intraperitoneal injections of OVCAR8-, HeyA8-, and iOvCa147-STK11KO cells, and respective controls. LKB1 loss exhibited a dramatic reduction on tumour burden and metastatic potential; in particular, OVCAR8-STK11KO tumours had evidence of extensive necrosis, apoptosis and hypoxia. Interestingly, LKB1 loss did not affect AMPKα phosphorylation in EOC spheroids and tumour xenografts, indicating that LKB1 signaling to support EOC cell survival in spheroids and metastatic tumour growth occurs via other downstream mediators. We identified the dual-specificity phosphatase DUSP4 as a commonly upregulated protein due to LKB1 loss; indeed, DUSP4 knockdown in HeyA8-STK11KO cells restored spheroid formation and viability. Our results strongly indicate that intact LKB1 activity independent of downstream AMPK signaling is required during EOC metastasis.
INTRODUCTION
Epithelial ovarian cancer (EOC) is a highly lethal malignancy in women since nearly all patients are diagnosed with metastatic disease, at which point the 5-year survival rate is only 30% [1] .
Standard-of-care for late-stage EOC has largely unchanged over 25 years and encompasses aggressive cytoreductive surgery with combination carboplatin/paclitaxel chemotherapy. Most patients initially respond to treatment, but recurrence and chemo-resistance is common and fatal in most cases. Therefore, the development of novel approaches to impede metastasis and recurrence of chemo-resistant disease will be paramount to improve outcomes for women diagnosed with EOC [2] .
A common symptom of advanced EOC is the accumulation of ascites within the peritoneal cavity [3] . This ascites often harbors individual malignant cells or those existing as multicellular aggregates, herein referred to as spheroids, the latter of which offer numerous selective advantages in the context of metastatic dissemination [4] . EOC spheroids exhibit anoikis resistance and possess an enhanced capacity to adhere to ECM and displace mesothelial cell monolayers [3; 5; 6] . In addition, recent evidence indicates that EOC spheroids seed peritoneal metastases that maintain the cellular heterogeneity of the primary tumour [7] . Thus, EOC spheroids likely play a key role in efficient intraperitoneal metastasis.
We previously reported that Liver kinase B1 (LKB1; encoded by the STK11 gene) is expressed in the majority of EOC cell lines and patient ascites-derived cells; importantly, transient knockdown of STK11 in EOC cells results in reduced spheroid viability and increased chemo-sensitization [8] . LKB1 is a ubiquitously-expressed, highly-conserved serine-threonine kinase that commonly acts as the upstream kinase for AMP-activated protein kinase (AMPK), primarily in regulating cell metabolism [9] . The LKB1-AMPK signaling axis functions as a sensor of energy status in the cell and enables adaptation to conditions that deplete intracellular ATP. Decreased ATP and the corresponding increase in AMP favors phosphorylation and activation of AMPK by LKB1, resulting in the coordinated downregulation of anabolic pathways and upregulation of catabolic pathways to restore energy homeostasis [10] .
LKB1 is often described as having tumour suppressor-like activity since specific cancers feature somatic alterations in the LKB1-encoding gene STK11 [11] [12] [13] or have decreased LKB1 protein expression [14; 15] . In addition, germline inactivating mutations in STK11 have been implicated in Peutz-Jeghers syndrome (PJS) [16] , which is characterized by the formation of benign polyps in the gastrointestinal tract and an increased risk for several cancers [17] . LKB1 loss has also been implicated in EOC initiation [15; 18] ; however, there is significant evidence suggesting that LKB1 and its direct signaling partners function in context-dependent, protumorigenic capacities [8; 19-22] .
To date, no studies have assessed the impact of LKB1 loss-of-function in mouse models of cancer metastasis, such as late-stage EOC. In this study, we sought to determine how complete LKB1 ablation in EOC cells would affect metastatic potential. We present evidence indicating that LKB1 loss decreases anchorage-independent viability of EOC cells and reduces the longterm spheroid maintenance. In a similar fashion, LKB1 loss in three independent EOC cell lines significantly reduced tumour burden and extended host survival in a xenograft mouse model of peritoneal metastasis. Based on these findings, we propose that strategies targeting LKB1 or its signaling partners would have therapeutic potential in metastatic EOC.
RESULTS

LKB1 lacks tumour suppressor-like activity in EOC
We previously reported that LKB1 protein is expressed in EOC tumour samples, and that transient STK11 knockdown decreases EOC spheroid viability and chemo-resistance, suggesting that LKB1 or its signaling partners might represent viable therapeutic targets in EOC [8] .
Therefore, we sought to investigate how sustained LKB1 loss would affect tumourigenic and metastatic potential in several different EOC cell lines. OVCAR8 (high-grade serous ovarian cancer; HGSOC) and HeyA8 (poorly-differentiated ovarian cancer) cells form robust spheroids as well as aggressive tumour growth in immune-compromised mice, and therefore represent two EOC cell lines with which to test our hypothesis regarding LKB1 function. The iOvCa147 cell line was derived by our group from the ascites of a heavily-treated HGSOC patient [23] . This cell line forms less dense yet viable spheroids, and establishes ascites and tumours in NOD/SCID mice with longer latency as compared with OVCAR8 and HeyA8 cells. We used CRISPR/Cas9-based genome editing to generate stable cell lines lacking LKB1 expression: OVCAR8-STK11KO, HeyA8-STK11KO, and iOvCa147-STK11KO, as well as one immortalized human fallopian tube secretory epithelial cell line (FT190-STK11KO) for comparison. Complete ablation of LKB1 expression was confirmed in each STK11KO cell line ( Figure 1A) . Under standard adherent culture conditions, STK11KO cell lines resembled parental controls with respect to morphology; iOvCa147-STK11KO cells were the notable exception and had a spindleshaped appearance compared to controls (Supplemental Figure S1 ). Stable LKB1 loss in our newly-derived STK11KO cell lines did not affect proliferation since doubling time was unchanged compared with parental cell lines ( Figure 1B) .
It is well-established that the majority of HGSOC likely originate in the secretory epithelium of the distal fimbriae of the fallopian tube [24] [25] [26] , and mouse models also support this as a primary cell-of-origin in this disease [27] [28] [29] . Two reports have implied that loss of LKB1 expression may be involved in the development of HGSOC [15; 18] whereas we have alternative conflicting data demonstrating that LKB1 is in fact expressed and functional in latestage EOC [8] . If LKB1 has tumour-suppressive properties in EOC, then STK11 knockout should enhance normal FT190 cell clonogenicity in both anchorage-dependent and -independent conditions. We performed clonogenic assays using each line harboring LKB1 loss to determine whether anchorage-dependent replicative potential would be affected by loss of LKB1 in FTE and EOC cells. We found that LKB1 loss significantly decreased clonogenic potential in FT190 cells, but not in any EOC cell lines tested (Supplemental Figure S2) .
Since anchorage-independence is a common feature of transformed cells and critical to EOC metastasis, we determined how LKB1 loss would affect anchorage-independence in normal FTE and transformed EOC cells. In contrast to the results from adherent clonogenic assays, loss of LKB1 significantly decreased soft agar colony number and colony size in HeyA8 cells ( Figure 1C & D) ; OVCAR8-STK11KO soft agar colony number was not different from parental controls, however colony size was significantly decreased (Figure 1C & D) . The iOvCa147 cell line has a very poor colony-forming capacity in soft agar and were thus not tested by this assay.
Furthermore, FT190 cells, which have been immortalized due to p53 and pRB inactivation by SV40 large T antigen [30] , were unable to establish any colonies in soft agar with or without intact LKB1 (data not shown). These results suggest that LKB1 does not possess overt tumour suppressive activity, but may be required for aggressive EOC cell growth or viability when in suspension.
LKB1 is required in EOC spheroids to maintain cell viability
Spheroids are frequently present in the peritoneal ascites of EOC patients, and facilitate peritoneal metastasis since they exhibit anoikis resistance, adhere to mesothelial cell monolayers [3; 5] , and help to establish peritoneal metastases [7] . We have demonstrated previously that decreased LKB1 expression by transient STK11 knockdown has little to no effect on the growth and viability of adherent proliferating EOC cells, yet viability is reduced in spheroids [8] . Thus, we sought to determine how sustained loss of LKB1 would affect FTE and EOC spheroid viability. We cultured FTE and EOC cells in ultra-low attachment (ULA) culture plates to force 
LKB1 is required to maintain EOC metastatic potential
The results of our in vitro studies indicate that LKB1 is required for both anchorageindependence and spheroid viability in EOC cells. Since spheroids play an important role in EOC metastasis, we sought to determine the effect of LKB1 loss in an in vivo xenograft model of peritoneal metastasis. EOC cells are injected directly into the peritoneal space of immunodeficient host mice to mimic metastasis, where tumour pathology and pattern of dissemination are similar to late-stage disease in patients [31] . We hypothesized that stable LKB1 ablation in EOC cells would decrease metastatic potential in vivo.
We found that survival was extended in hosts for all three STK11KO cell lines when compared with parental cell lines ( Figure 3A) Frequency of ascites accumulation was decreased in OVCAR8-STK11KO relative to OVCAR8 injected mice, but overall dissemination patterns were similar, indicating that metastatic trajectory was unchanged by LKB1 loss ( Figure 3B and Supplementary Table S1).
Macroscopic tumour burden in OVCAR8-STK11KO injected hosts was significantly decreased compared to OVCAR8 cells ( Figure 3B ). In mice injected with HeyA8-STK11KO cells and Table S1 ). In contrast, HeyA8-injected hosts had several large and solitary solid tumour masses at the omentum and lower peritoneal cavity, often adherent to the intestine and uterus ( Figure 3B and Supplementary Table S1 ). This resulted in a total tumour burden that was significantly reduced in HeyA8-STK11KO injected mice as compared with HeyA8 controls ( Figure 3C ). Sustained LKB1 loss was confirmed by immunoblotting of protein lysates from excised OVCAR8-and HeyA8-STK11KO tumours ( Figure 3D ). Similar to our in vitro spheroid assays, we observed the most striking effects of LKB1 loss in the iOvCa147 cell line, which was originally generated from the ascites of a high-grade serous ovarian cancer patient by our group [23] . In line with the extended survival of iOvCa147-STK11KO hosts ( Figure 3A) , peritoneal colonization was substantially diminished, with most mice exhibiting little evidence of macroscopically-observable peritoneal tumours upon necropsy 
LKB1-independent AMPK phosphorylation in EOC cells, spheroids and xenograft tumours
We demonstrated previously that both LKB1 and phosphorylated AMPKα are coordinately upregulated in EOC spheroids [8] , suggesting that LKB1-AMPK signaling is activated during EOC metastasis. Since LKB1 is commonly described as the major upstream kinase responsible for phosphorylation of AMPKα at Thr172 [9] , we expected that phospho-AMPKα would be substantially decreased or ablated in STK11KO spheroids relative to parental controls. Instead, we found that phospho-AMPKα Thr172 was maintained in spheroids for all STK11KO cell lines tested ( Figure 5A ), indicating that in FTE and EOC spheroids AMPKα is phosphorylated by one or more other kinases independently of LKB1.
Ca(2+)/calmodulin-dependent kinase kinase-beta (CAMKK2) is one principal alternative AMPK upstream kinase [33] , and cell detachment can rapidly induce phospho-AMPKα at T172 in a CAMKK2-dependent manner in breast cancer cells [34] . Therefore, we treated FT190-STK11KO, OVCAR8-STK11KO, and iOvCa147-STK11KO spheroids and parental cell line controls with STO-609, a potent cell-permeable inhibitor of CAMKK2 [35] . substantially decreased phospho-AMPKα in adherent cells and spheroids for all cell lines tested
(
Figure 5B), indicating that CAMKK2 is likely the major activating kinase for AMPKα in FTE and EOC cells, whether LKB1 is present or not. Importantly, analysis of tumour xenografts revealed that phospho-AMPKα was unaffected by loss of LKB1, also ( Figure 5C & D) . Indeed, LKB1 loss had no effect on OVCAR8 cells when subjected to several metabolic stressorsglucose deprivation, serum starvation, mitochondrial inhibition, and AMP mimetic treatmentwhich act through AMPK activity (Supplemental Figure S4) . Taken together, these results imply that any of our observed phenotypic effects due to LKB1 loss in FTE and EOC cells and spheroids, and during EOC metastasis in mice, are most likely AMPK-independent.
DUSP4 is upregulated due to sustained LKB1 loss
Since it appeared that AMPK was not mediating the phenotypic changes in EOC spheroids and tumours due to LKB1 loss, we sought to discover other potential effectors. To do so, we performed reverse phase protein array (RPPA) analysis comparing STK11KO knockout cells grown in adherent and spheroid culture using both OVCAR8 and HeyA8 cells. From this data, we observed distinct differences in protein expression between the OVCAR8 and HeyA8 spheroids due to LKB1 loss (Figure 6A and Supplementary Table S2) , which may reflect the differences seen in spheroid culture and xenograft experiments between these two distinct EOC cell lines. However, one protein that was consistently increased due to LKB1 loss in both adherent cells and even more so in spheroids was dual-specificity phosphatase 4 (DUSP4). We observed a 1.86-2.06-fold increase in OVCAR8-STK11 adherent cells and 1.76-2.57-fold increase in spheroid culture; in HeyA8-STK11KO cells, DUSP4 protein was elevated by 2.37-2.76-fold in adherent and 2.84-3.12-fold in spheroids. We confirmed this increase in DUSP4 protein expression among all three EOC cell lines where LKB1 was ablated ( Figure 6B ). In addition, DUSP4 was increased significantly in OVCAR8-STK11KO xenografts as compared with tumours derived from OVCAR8 cells (Figure 6C and 6D ).
DUSP4 is a dual-specificity phosphatase that typically targets several MAPKs to decrease their phosphorylation state and thus downstream signaling activity [36] . To this end, we performed immunoblot analysis of phosphorylated ERK, JNK and p38 among the three EOC cell lines lacking LKB1 as compared with controls. Interestingly, phospho-ERK1/2 was consistently decreased in EOC cells upon spheroid culture, however levels of phospho-p38 and phospho-JNK (p54 and p46) were either unchanged or different among the three cell lines (Supplementary Figure S5) . Levels of phosphorylated ERK, JNK and p38, however, yielded no change due to LKB1 loss even though DUSP4 protein is universally increased in these cell lines. To further investigate whether upregulation of DUSP4 protein may impact the spheroid phenotype (i.e., reduced formation potential and cell viability) due to LKB1 loss, we performed transient DUSP4 knockdown in HeyA8 and HeyA8-STK11KO cells ( Figure 6E ) and subsequently formed spheroids. We observed a restoration of intact spheroid formation by DUSP4 knockdown in HeyA8-STK11KO spheroids (Figure 6F) , as well as increased cell viability to levels similar to control HeyA8 spheroids ( Figure 6G) . Therefore, we speculate that DUSP4 is at least one protein mediating the reduced metastatic potential due to LKB1 loss in our in vitro spheroid model, and potentially decreased tumour formation and metastasis in vivo.
DISCUSSION
Peritoneal metastasis in EOC is often associated with the accumulation of malignant ascites, which contains spheroids that play a key role in disease progression [3] . We previously reported that EOC cells require LKB1 to maintain spheroid viability and chemo-resistance [8] . Given the functional relevance of spheroids in EOC metastasis [3; 5-7] , targeting LKB1 or its signaling partners in metastatic EOC may have therapeutic value. Herein, we now present additional evidence that EOC cells require LKB1 for maximal metastatic potential and add to the body of literature indicating that LKB1 can function in a pro-oncogenic capacity to promote disease progression. Based on our findings, and those of others, we propose that LKB1 or its AMPKindependent signaling partners may represent therapeutic vulnerabilities in metastatic EOC.
In the context of cancer, LKB1 has been commonly described as possessing tumour suppressor-like function. STK11 is frequently deleted in non-small cell lung cancer (NSCLC) [37] , and somatic nonsense mutations in STK11 occur with high frequency in primary lung carcinomas and lung cancer cell lines [12] , as well as in 20% of cervical cancer [13] and melanoma [11] . Loss of LKB1 in the ovarian surface epithelium has been linked to papillary serous ovarian cancer in a mouse model [18] . LKB1 protein expression is decreased in HGSOC relative to normal FTE tissue; however, this study also found that genomic loss of both STK11 alleles was associated with improved patient survival [15] . In fact, our previous report [8] demonstrated that LKB1 expression is maintained in late-stage EOC and is required for cell survival in spheroids and promotes platinum resistance. Given that FTE cells are the most likely cell-of-origin in HGSOC, we had the direct ability to determine whether LKB1 may act as a tumour suppressor in FT190 cells with its loss resulting in their oncogenic transformation.
However, we found that neither cell proliferation, nor colony formation, nor anchorageindependence, nor spheroid viability and growth were increased due to STK11 gene inactivation.
Since FT190 cells are immortalized by expression of SV40 large T antigen [30] , our results also indicate that the combination of p53 and pRb inactivation with LKB1 loss is insufficient for malignant transformation of FTE cells. Given the report suggesting decreased LKB1 protein expression in pre-malignant STIC lesions and primary serous ovarian tumours [15] , we propose that LKB1 re-expression and its pro-metastatic effects are manifest at later steps in ovarian tumorigenesis after initial neoplastic transformation.
A growing body of evidence suggests that LKB1 can function in context-dependent, protumorigenic capacities. In line with its role in metabolism, deficiencies in LKB1-AMPK signaling sensitize some cancer cells to energy stress. LKB1-deficient NSCLC cells are more sensitive to the mitochondrial complex I inhibitor phenformin compared to NSCLC cells with intact LKB1 [38] , and AMPK is required in A549 lung cancer cells for survival under glucosedeprived culture conditions [20] . However, LKB1 may also promote oncogenic potential in ways that are not directly linked to the energy stress response. Expression of LKB1 protein is associated with poor patient prognosis in hepatocellular carcinoma, and ectopic expression of LKB1 in Hep3B cells increases tumour xenograft growth [39] . Similar to our study of EOC cells, STK11 knockdown decreases spheroid formation and clonogenicity of MCF-7 cells, indicating that LKB1 can enhance anchorage-independence and replicative potential in breast cancer cells [22] . We have not yet elucidated the mechanisms by which LKB1 promotes metastatic potential of EOC cells; however, our data provide additional evidence to support its pro-tumorigenic role in yet another cancer-specific context. During metastasis, cancer cells must overcome significant hurdles to maintain viability and seed the formation of secondary tumours. Enhanced anoikis resistance is associated with greater aggressiveness and tumorigenicity in in vivo models of EOC [40] . We found that LKB1 loss had little effect on EOC cell growth under standard adherent culture conditions, while having a clear negative impact on EOC cell viability in suspension. Our findings imply that LKB1 supports anoikis resistance and anchorage-independence in EOC cells through mechanisms that do not involve AMPK. We previously reported that phosphorylation of AMPKα at Thr172, which is required for its full catalytic activity [41] , is induced upon EOC spheroid formation [8] . Herein, we show that despite LKB1 loss, phospho-AMPKα levels in FTE and EOC spheroids remain elevated, which implies AMPKα activation occurs independently of LKB1 in our spheroid system. One such alternative kinase is CAMKK2 [33] , which has been implicated in cell detachment-induced phosphorylation of AMPKα in several breast cancer cell lines [34] . Using STO-609, we provide evidence that AMPKα phosphorylation in FTE and EOC spheroids is largely mediated by CAMKK2. In fact, CAMKK2 inhibition using STO-609 does not affect EOC spheroid cell viability (Laski and Shepherd, unpublished), which corroborates our previous finding that knockdown of PRKAA1/2 encoding AMPK catalytic subunits [8] . Thus, we conclude that phospho-AMPK is induced via CAMKK2 in EOC spheroids, but that AMPK activity is dispensable for maintaining spheroid cell viability in the context of LKB1 activity. While AMPKα is often described as the primary cell stress signaling mediator downstream of LKB1, we demonstrate that essential LKB1 functions in EOC metastasis are AMPKindependent. LKB1 is known to phosphorylate at least 12 substrates that are similar in structure to AMPK, collectively termed AMPK-related kinases. Broadly, these kinases can regulate cell polarity, migration, and metabolism in specific cell contexts [42] . Salt-inducible kinases SIK2 and SIK3 may be required in HGSOC metastasis, but their dependence on LKB1 in this disease is unknown [43] [44] [45] . AMPK-related kinase ARK5/NUAK1 has been reported to be overexpressed in EOC and implicated in the regulation of EMT [46] . In line with this, NUAK1 expression in EOC is associated with poor patient prognosis [47] . Our group is currently pursuing additional NUAK1 functions as a substrate of LKB1 in metastatic EOC. Elucidation of these downstream mediators will likely be of clinical relevance since they may represent more specific and suitable therapeutic targets in metastatic EOC than LKB1 itself.
We postulate that EOC cells are adaptively reprogrammed to handle abrogated stress signaling due to sustained LKB1 loss. DUSP4 is commonly increased in NSCLC tumours possessing STK11 loss-of-function mutations. Kaufman et al [48] identified an upregulated 16-gene expression signature, which included DUSP4, in LKB1-deficient NSCLC cells likely due to an altered oxidative stress response mediated by NRF2. We postulate that there is a similar dysregulated response to oxidative stress and hypoxia in the absence of LKB1 function in EOC spheroids and tumour xenografts. This could explain our observation of elevated hypoxia in OVCAR8-STK11KO xenograft tumours correlating with increased DUSP4 expression, perhaps resulting from chronic stress due to LKB1 loss in this cell line. It would be intriguing to study whether LKB1 signaling is required in response to tumour hypoxia and oxidative stress to regulate a downstream transcriptional network and mitigate these key metabolic stresses in cancer.
While LKB1 may act as a tumour suppressor in other cancers, we have provided additional evidence that LKB1 clearly possesses important functions in a pro-metastatic capacity during EOC progression. Consistent with the established notion that three-dimensional spheroids contribute to EOC dissemination, we have demonstrated that intact LKB1 is required in both in vitro spheroid and in vivo xenograft models of metastatic disease. Overall, we provide supportive evidence that LKB1 or its direct signaling partners represent viable therapeutic targets in metastatic EOC.
MATERIALS AND METHODS
Cultured cell lines
OVCAR8 and HeyA8 cell lines were cultured in RPMI-1640 (Wisent). FT190 and iOvCa147 cell lines were cultured in DMEM/F12 (Life Technologies). For all cell lines, growth medium was supplemented with 10% FBS. OVCAR8 and HeyA8 cells were obtained from the American Type Culture Collection and iOvCa147 cells were generated by us as described previously [23] .
The immortalized human fallopian tube secretory epithelial cell line FT190 [30] was provided by R. Drapkin (University of Pennsylvania). All cell lines were authenticated by short tandem repeat analysis performed by The Centre for Applied Genomics (The Hospital for Sick Children, Toronto, ON, Canada), and routinely tested for mycoplasma using the Universal Mycoplasma Detection Kit (30-1012K, ATCC) or as performed by IDEXX BioResearch (Columbia, MO, USA) prior to xenograft experiments.
Generation of STK11KO cell lines
The 20-nucleotide guide sequence targeting the STK11 gene 5'-AGCTT GGCCC GCTTG CGGCG-3' was selected using CRISPR Design Tool (http://tools.genome-engineering.org).
Complementary oligonucleotides 5'-CACCG AGCTT GGCCC GCTTG CGGCG-3' and 5'-AAACC GCCGC AAGCG GGCCA AGCTC-3' (Sigma-Genosys) were annealed and ligated into the BbsI-digested restriction endonuclease site of pSpCas9(BB)-2A-Puro plasmid (gift from Dr. F. Dick, Western University) as per the protocol described in Ran et al. [49] to generate the pSpCas9-sgSTK11 plasmid. Cells were transfected with pSpCas9-sgSTK11 plasmid using LipofectAMINE 2000 (Invitrogen) according to manufacturer's instructions, followed by treatment with 1 μg/mL puromycin for one day. After growth recovery, limiting dilution subcloning of potential STK11-knockout cells was performed and confirmation of STK11 knockout by western blotting for LKB1 expression. A minimum of five clones lacking LKB1 protein expression were positively identified and subsequently mixed in equal ratios to generate the STK11KO cell line populations.
Antibodies and reagents
Antibodies against LKB1 (#3050S), phospho-AMPKα (T172) (#2535S), AMPKα (#5832S), phospho-p44/42 ERK (T202/Y204) (#9101S), phospho-JNK (T183/Y185) (#4668P), phosphop38 (T180/Y182) (#4511S), and DUSP4 (#5149S) were purchased from Cell Signaling (Danvers, MA) and used at 1:1000 in 5% bovine serum albumin (BSA)/TBS-T. Antibody against CA9 (AF2188; 1 μg/mL) was purchased from R&D Systems (Minneapolis, MN). Antibody against tubulin (T5168; 1:8000) and vinculin (V9264; 1:50 000) were purchased from Sigma (St. Louis, MO). Antibody against vinculin was purchased from HRP-conjugated antibodies against mouse IgG (NA931V; 1:10 000) and rabbit IgG (NA934V; 1:10 000) were purchased from Sigma. 
Immunoblot analysis
Isolation of protein lysates and western blotting were performed as described previously [8] .
Doubling time determination in adherent culture
Cells were seeded into 96-well adherent culture plates at a density of 1000 cells per well. Phasecontrast images were captured at 3-hour intervals for a total of 96 hours and confluence was measured using the IncuCyte Zoom imaging platform. Doubling time was determined by fitting an exponential growth curve to the confluence-over-time data (GraphPad Prism 6.05).
Clonogenic assays
Cells were seeded at specific cell densities then fixed and stained when cells formed well-defined 1000 cells/10-cm plate, 12 days. Cells were fixed and stained using the Protocol Hema 3 staining kit (Fisher Scientific). Colony number and size were determined using the Fiji Is Just ImageJ (Fiji) image processing software package [50] ; the Trainable Weka Segmentation plugin [51] was used to generate classifiers to segment images into stained colonies and background. Images were converted into binary colour, "fill holes" and "watershed" functions were applied, and pixel-to-distance scale was set using the culture vessel diameter. Colony number and area were determined using the "analyze particles" function to outline each colony as a region of interest and provide colony counts.
Soft agar assays
EOC cells were suspended at a density of 25 000 cells/1.5 mL in medium supplemented with 10% FBS and 1% melted soft agar; this suspension was added to each well containing solidified 2% agar. Additional growth medium was then added to each well, and plates were incubated for 14 days. Images of random fields of view were captured at 25x magnification using a Leica DMI 4000B inverted microscope. Colony number and size were determined using the Fiji image processing software package as described above.
Spheroid viability assay
Cells were seeded into 24-well ULA cluster plates (50 000 cells per well in a volume of 1 mL).
At the specified time points, the entire contents of each well were collected and trypsinized at 37°C with gentle agitation every 10 min until aggregates were no longer visible (10-30 min).
Trypsin was inactivated and Trypan Blue Exclusion cell counting was performed using a TC10 Automated Cell Counter (Bio-Rad). For long-term spheroid growth assays, cells were seeded into a 96-well round-bottom ULA plate at a density of 2000 cells/well. Phase-contrast images were captured at 2-hour intervals for up to 12 days using the IncuCyte Zoom imaging platform.
Single spheroids were isolated at specific time points post-seeding (3, 7, 14, and 21 days) and transferred into separate wells of a 48-well adherent culture plate, incubated for 2 days, then attached spheroids were fixed and stained using the Protocol Hema 3 staining kit (Fisher Scientific).
Xenotransplantation assays
NOD/SCID female mice (8-10 weeks old; Charles River) were inoculated by intraperitoneal injection with 150 µL of PBS containing the following numbers of cells: OVCAR8/OVCAR8-STK11KO, 4 x 10 6 ; HeyA8/HeyA8-STK11KO, 1 x 10 6 ; iOvCa147/iOvCa147-STK11KO, 2 x 10 6 .
For survival analyses (OVCAR8, OVCAR8-STK11KO, HeyA8, HeyA8-STK11KO, iOvCa147
and iOvCa147-STK11KO cells), mice were monitored daily after intraperitoneal injection and euthanized using standard criteria for humane endpoints (i.e., lethargy, hunched posture, impaired breathing, extreme weight loss, excessive ascites). Mice were provided chow (cat. no.
2919, Envigo) and water ad libitum throughout the study. All animal experiments were approved by Institutional Animal Care and Use Committee of the University of Western Ontario and carried out in accordance with the approved guidelines.
Inhibition of CAMKK2
Cells were seeded into a 6-well adherent culture plate, and treatment was initiated the following day with 10 μM STO-609 or an equivalent volume of DMSO. For analysis of spheroids, cells
were seeded into a 6-well ULA plate and treated with 10 μM STO-609 or DMSO at the time of seeding. Lysates were generated for immunoblot analysis at 24 h (FT190, FT190-STK11KO, iOvCa147 and iOvCa147-STK11KO cells) or 72 h (OVCAR8 and OVCAR8-STK11KO cells).
Induction of metabolic stress
For glucose deprivation experiments, cells were seeded into 96-well adherent culture plates Normalized data and log2-fold changes are summarized in Supplementary Table S2 . A heat map was generated using log2-fold change data and the Matrix2png interface (https://matrix2png.msl.ubc.ca).
DUSP4 knockdown
Transfections were performed of cells seeded in 6-well plates using DharmaFECT1 as per 
Statistical analysis
All statistical analyses were performed using GraphPad Prism 6.05 (GraphPad Software, San
Diego, CA). The results from in vitro analyses were assessed using a two-tailed Student's t-test or two-way ANOVA with Tukey's multiple comparisons test. Tumour latency analysis in mice was tested for significance using the log-rank test. In all cases, a p-value of less than 0.05 was considered statistically significant. HeyA8-STK11KO spheroids due to DUSP4 knockdown as determined by Cell-Titer Glo assay in a 96-well ULA format. Two-way ANOVA and Tukey's multiple comparisons test was performed (****, p < 0.0001). 
